Zena Werb

San Francisco General Hospital — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

168h-index143.0kcitations582works3.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protease and Inhibitor Mechanisms(215), Peptidase Inhibition and Analysis(83), Cancer Cells and Metastasis(80), Cell Adhesion Molecules Research(71), Blood Coagulation and Thrombosis Mechanisms(52)

Publications579 total

Platelet Molecular Maturation Links Platelet Aging and the Platelet Storage Lesion
2026Open Access
Neoplastic Immune Mimicry Potentiates Breast Tumor Progression
Cancer Research·2025Open Access
Tumor cell-adipocyte gap junctions activate lipolysis and contribute to breast tumorigenesis
Nature Communications·2025· 3 citedOpen Access
Abstract LB178: Neoplastic immune mimicry is a generalizable phenomenon in breast cancer and epithelial CD69 enables early tumor progression
Cancer Research·2025
Neoplastic immune mimicry potentiates breast tumor progression
2025· 1 citedOpen Access
Single-cell analysis of breast cancer metastasis reveals epithelial-mesenchymal plasticity signatures associated with poor outcomes
Journal of Clinical Investigation·2024· 17 citedOpen Access
Abstract LB224: Neoplastic immune mimicry potentiates breast cancer progression
Cancer Research·2024
Data from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression
2023Open Access
Supplementary Materials and Methods from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression
2023Open Access
Supplementary Table 1 from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression
2023Open Access
Supplementary Methods, Figures 1-4, Movie Legend, Table Legends 1-5 from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression
2023Open Access
Supplementary Table 5 from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression
2023Open Access
Supplementary Table 2 from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression
2023Open Access
Supplementary Table 3 from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression
2023Open Access
Supplementary Table 5 from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression
2023Open Access
Supplementary Methods, Figures 1-4, Movie Legend, Table Legends 1-5 from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression
2023Open Access
Supplementary Table 3 from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression
2023Open Access
Supplementary Movie from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression
2023Open Access
Supplementary Table 1 from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression
2023Open Access
Supplementary Materials and Methods from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression
2023Open Access
page 1 of 29Next →

Frequent Co-authors

Kai Kessenbrock(6), Valerie M. Weaver(4), Thiennu H. Vu(4), Mina J. Bissell(4), Mikala Egeblad(3), Vicki Plaks(3), Mark D. Sternlicht(3), Andrew J. Ewald(3), Gabriele Bergers(3), Douglas Hanahan(3), Beate Heissig(3), Neil R. Hackett(3), Ronald G. Crystal(3), David Lyden(3), Shahin Rafii(3), Lisa M. Coussens(2), Pengfei Lu(2), Dieter E. Jenne(2), Ken Takai(2), Juliane Winkler(2)